| MAbs | Monoclonal Antibodies |
|---|---|
| Mabs | monoclonal antibodies |
| MAS | magic angle spinning; Manifest Anxiety Scale; maximum average score; McCune-Albright syndrome; mecon... |
| AMA | 1) Anti-Mitochondrial Antibodies 2) American Medical Association |
| Anti-LKM | Antibodies to Liver-Kidney Microsome |
| Bi-MAbs | Bispecific monoclonal antibodies |
|---|---|
| HuMAbs | Human monoclonal antibodies |
| MAbs | Monoclonal antibodies |
| McAbs | Monoclonal Antibodies |
| MA | Monoclonal antibodies |
| antibodies, monoclonal | Antibodies produced by clones of cells such as those isolated after hybridization of activated b lymphocytes with neoplastic cells. These hybrids are often referred to as hybridomas. (12 Dec 1998) |
|---|
| monoclonal antibodies | Identical antibodies that are made in large amounts in the laboratory. Doctors are studying ways of using monoclonal antibodies to treat leukaemia. (12 Dec 1998) |
|---|---|
| monoclonal | 1. <cell biology> Used of a cell line whether within the body or in culture to indicate that it has a single clonal origin. 2. <immunology> Monoclonal antibodies are produced by a single clone of hybridoma cells and are therefore a single species of antibody molecule. (18 Nov 1997) |
| monoclonal antibody | <immunology, molecular biology> A substance, usually a protein, which can be synthsised in the laboratory in pure form by a single clone (population) of cells. These antibodies can be made in large quantities and have a specific affinity for certain target molecules called antigens which can be found on the surface of cells and those that are malignant. Monoclonal antibodies are currently being investigated as a possible form of cancer treatment although their benefit has not be fully proven. (16 Dec 1997) |
| monoclonal gammopathies, benign | Conditions characterised by the presence of a monoclonal serum (or urine) protein without clinical manifestations of plasma cell dyscrasia. (12 Dec 1998) |
| monoclonal immunoglobulin | A homogenous immunoglobulin resulting from the proliferation of a single clone of plasma cells and which, during electrophoresis of serum, appears as a narrow band or "spike"; it is characterised by heavy chains of a single class and subclass, and light chains of a single type. Synonym: M protein, monoclonal protein, paraprotein. (05 Mar 2000) |
| monoclonal peak | A narrow band visible on electrophoresis or an abnormal arc seen on immunoelectrophoresis, thought to represent immunoglobulin of one cell clone. (05 Mar 2000) |
| monoclonal protein | A homogenous immunoglobulin resulting from the proliferation of a single clone of plasma cells and which, during electrophoresis of serum, appears as a narrow band or "spike"; it is characterised by heavy chains of a single class and subclass, and light chains of a single type. Synonym: M protein, monoclonal protein, paraprotein. (05 Mar 2000) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| antibodies | Any of numerous protein molecules produced by the B-cells as a primary immune defense. (16 Dec 1997) |
| antibodies, anticardiolipin | Antiphospholipid antibodies found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase immunoassay employing the purified phospholipid antigen cardiolipin. (12 Dec 1998) |
| antibodies, anti-idiotypic | Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies. (12 Dec 1998) |
| antibodies, antineutrophil cytoplasmic | Autoantibodies directed against cytoplasmic constituents of polymorphonuclear leukocytes and/or monocytes. They are used as specific markers for wegener's granulomatosis and other diseases, though their pathophysiological role is not clear. Anca are routinely detected by indirect immunofluorescence with three different patterns: c-anca (cytoplasmic), p-anca (perinuclear), and atypical anca. (12 Dec 1998) |
| antibodies, antinuclear | See: Antinuclear antibodies. (12 Dec 1998) |
| antibodies, antiphospholipid | Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals. (12 Dec 1998) |
| antibodies, archaeal | Immunoglobulins induced by substances elaborated by archaea that have an antigenic activity. (12 Dec 1998) |
Synonyms :
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|